Kenvue Inc. $KVUE Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. decreased its position in shares of Kenvue Inc. (NYSE:KVUE) by 14.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 252,166 shares of the company’s stock after selling 43,368 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Kenvue were worth $4,093,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Norges Bank acquired a new stake in shares of Kenvue in the 2nd quarter worth about $537,418,000. Independent Franchise Partners LLP grew its position in Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after purchasing an additional 21,886,537 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Kenvue by 38.6% in the second quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after purchasing an additional 8,436,166 shares during the period. Amundi raised its holdings in shares of Kenvue by 82.5% during the second quarter. Amundi now owns 14,509,890 shares of the company’s stock valued at $305,446,000 after buying an additional 6,559,261 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Kenvue by 1.8% during the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after buying an additional 4,101,880 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of recent analyst reports. Jefferies Financial Group lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Edward Jones lowered Kenvue from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Deutsche Bank Aktiengesellschaft set a $18.00 price objective on shares of Kenvue in a report on Friday, October 24th. Finally, Evercore set a $18.00 target price on shares of Kenvue in a research report on Tuesday, October 28th. Four equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $19.46.

Kenvue Price Performance

NYSE KVUE opened at $18.50 on Thursday. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17. The company has a market cap of $35.44 billion, a PE ratio of 24.67 and a beta of 0.59. The stock’s 50-day moving average price is $17.32 and its two-hundred day moving average price is $17.78.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th will be given a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.5%. The ex-dividend date is Wednesday, February 11th. Kenvue’s dividend payout ratio is 110.67%.

Insider Buying and Selling

In other news, Director Jeffrey C. Smith acquired 3,200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was purchased at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the purchase, the director owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 1.68% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.